{"id":7081,"date":"2023-07-18T16:41:00","date_gmt":"2023-07-18T14:41:00","guid":{"rendered":"https:\/\/www.incuballiance.fr\/?p=7081"},"modified":"2025-10-07T16:55:27","modified_gmt":"2025-10-07T14:55:27","slug":"theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros","status":"publish","type":"post","link":"https:\/\/www.incuballiance.fr\/en\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros","title":{"rendered":"\u00a0Theranexus announces a fundraising round of 3.1 million euros"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>Theranexus, an innovative biopharmaceutical company in the treatment of rare neurological diseases, which has gone through the ranks of IncubAlliance, announces a fundraising of 3.1 million euros.<br><\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A spin-off from the CEA (French Alternative Energies and Atomic Energy Commission), specializing in the treatment of rare neurological diseases and a pioneer in the development of drug candidates targeting both neurons and glial cells, Theranexus has come a long way since its graduation from IncubAlliance. Listed on the Euronext Growth market in Paris, the company today announced the completion of a \u20ac3.1 million funding round, of which approximately \u20ac2.5 million was subscribed by specialized and strategic investors through an accelerated book-building process, and \u20ac0.6 million by individual investors via the PrimaryBid platform.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Currently possessing a unique platform for identifying and characterizing innovative therapy drug candidates in the field of rare neurological disorders, and with its first drug candidate in clinical development for Batten disease, Theranexus intends to accelerate its growth with this fundraising round. Combined with the company&#039;s existing funds, the proceeds from this round will contribute to financing the pivotal Phase 3 trial of the drug candidate Batten-1, designed to treat pediatric patients with Batten disease, a rare neurological disorder. This Phase 3 trial is expected to begin at the end of the second half of 2023 and conclude at the end of 2026, with estimated costs of \u20ac5 million per year for three years. The funds raised will also be used to finance the company&#039;s other research and development activities, as well as its general operating needs.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>\u00abWe thank all our investors and new shareholders for their trust and commitment to this transaction. We also wish to acknowledge the participation of the BBDF Foundation, which has renewed its confidence in our ability to successfully develop Batten-1 to provide a therapeutic solution for patients with Batten disease. We are also delighted by the participation of individual investors through the PrimaryBid platform. Thanks to the validation of the Phase 3 design, the encouraging preliminary Phase I\/II results, and the success of this transaction, we will launch the pivotal Phase 3 trial of Batten-1 by the end of 2023. We are aiming for its approval and commercialization by 2027, which would make Batten-1 the first approved product for Batten disease worldwide.\u00bb<\/em>, concludes Mathieu Charv\u00e9riat, CEO of Theranexus.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>To learn more about Theranexus:&nbsp;<\/strong><a href=\"https:\/\/www.theranexus.com\/fr\/\">https:\/\/www.theranexus.com\/fr\/<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Theranexus, an innovative biopharmaceutical company specializing in the treatment of rare neurological diseases and a graduate of IncubAlliance, has announced a \u20ac3.1 million funding round. A spin-off from the CEA (French Alternative Energies and Atomic Energy Commission), specializing in the treatment of rare neurological diseases and a pioneer in the development of drug candidates targeting both neurons and glial cells, Theranexus has come a long way since its IncubAlliance launch. Listed on the Euronext Growth market in Paris, the company today announced the completion of a \u20ac3.1 million funding round, of which approximately \u20ac2.5 million was subscribed by specialized and strategic investors through an accelerated book-building process, and \u20ac0.6 million by individual investors via the PrimaryBid platform. Currently possessing a unique platform for identifying and characterizing innovative therapy drug candidates in the field of rare neurological disorders, and with its first drug candidate in clinical development for Batten disease, Theranexus intends to accelerate its growth with this fundraising round. Combined with the company&#039;s existing funds, the proceeds from this round will contribute to financing the pivotal Phase 3 trial of the drug candidate Batten-1, designed to treat pediatric patients with Batten disease, a rare neurological disorder. This Phase 3 trial is expected to begin at the end of the second half of 2023 and conclude at the end of 2026, with estimated costs of \u20ac5 million per year for three years. The funds raised will also be used to finance the company&#039;s other research and development activities, as well as its general operating needs. &quot;We thank all our investors and new shareholders for their trust and commitment to this transaction.&quot; We would also like to acknowledge the participation of the BBDF Foundation, which has renewed its confidence in our ability to successfully develop Batten-1 to provide a therapeutic solution for patients with Batten disease. We are also delighted by the participation of individual investors through the PrimaryBid platform. Thanks to the validation of the Phase 3 design, the encouraging preliminary Phase I\/II results, and the success of this transaction, we will launch the pivotal Phase 3 trial of Batten-1 by the end of 2023. We are aiming for its approval and commercialization by 2027, which would make Batten-1 the first approved product for Batten disease worldwide,\u00ab concludes Mathieu Charv\u00e9riat, CEO of Theranexus. To learn more about Theranexus: https:\/\/www.theranexus.com\/fr\/<\/p>","protected":false},"author":3,"featured_media":8453,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[10],"tags":[],"class_list":["post-7081","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\u00a0Theranexus annonce une lev\u00e9e de fonds de 3,1 millions d\u2019euros - IncubAlliance<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.incuballiance.fr\/en\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u00a0Theranexus annonce une lev\u00e9e de fonds de 3,1 millions d\u2019euros - IncubAlliance\" \/>\n<meta property=\"og:description\" content=\"Soci\u00e9t\u00e9 biopharmaceutique innovante dans le traitement des maladies neurologiques rares, pass\u00e9e par les rangs d\u2019IncubAlliance, Theranexus annonce une lev\u00e9e de fonds de 3,1 millions d\u2019euros. Issue du CEA, sp\u00e9cialis\u00e9e dans le traitement des maladies neurologiques rares et pionni\u00e8re dans le d\u00e9veloppement de candidats m\u00e9dicaments ciblant \u00e0 la fois les neurones et les cellules gliales, Theranexus en a fait du chemin depuis sa sortie d\u2019IncubAlliance. Cot\u00e9e sur le march\u00e9 Euronext Growth \u00e0 Paris, la soci\u00e9t\u00e9 annonce aujourd\u2019hui la r\u00e9alisation d\u2019une lev\u00e9e de fonds de 3,1 millions d\u2019euros,\u00a0dont environ 2,5 millions d\u2019euros ont \u00e9t\u00e9 souscrits par des investisseurs sp\u00e9cialis\u00e9s et strat\u00e9giques, via la construction acc\u00e9l\u00e9r\u00e9e d\u2019un livre d\u2019ordres, et 0,6 million d\u2019euros souscrits par des investisseurs particuliers via la plateforme PrimaryBid. Disposant actuellement d\u2019une plateforme unique d\u2019identification de caract\u00e9risation de candidats m\u00e9dicaments de th\u00e9rapie innovante dans le domaine des troubles neurologiques rares et d\u2019un premier candidat m\u00e9dicament en d\u00e9veloppement clinique dans la maladie de Batten, Theranexus entend donc passer \u00e0 la vitesse sup\u00e9rieure gr\u00e2ce \u00e0 cette lev\u00e9e de fonds. Combin\u00e9 aux fonds existant de la soci\u00e9t\u00e9, le produit de cette lev\u00e9e contribuera en effet au financement de la phase 3 pivot du candidat m\u00e9dicament Batten-1, visant \u00e0 soigner les patients p\u00e9diatriques atteints d\u2019une maladie neurologique rare, la maladie de Batten. Une phase 3 qui devrait d\u00e9buter d\u00e8s la fin du second semestre 2023 et s\u2019achever fin 2026, avec des co\u00fbts estim\u00e9s \u00e0 5 millions d\u2019euros par an pendant 3 ans. Les fonds de cette lev\u00e9e seront \u00e9galement destin\u00e9s \u00e0 financer les autres activit\u00e9s de recherche et d\u00e9veloppement de la soci\u00e9t\u00e9\u0301, ainsi que ses besoins g\u00e9n\u00e9raux. \u00ab Nous remercions tous nos investisseurs et nouveaux actionnaires pour leur confiance et leur engagement \u00e0 nos c\u00f4t\u00e9s dans cette op\u00e9ration. Nous tenons \u00e9galement \u00e0 saluer la participation de la Fondation BBDF qui a renouvel\u00e9\u0301 sa confiance dans notre capacit\u00e9\u0301 \u00e0 mener \u00e0 bien le d\u00e9veloppement de Batten-1 afin d\u2019apporter une solution th\u00e9rapeutique aux patients atteints par la maladie de Batten. Nous nous r\u00e9jouissons \u00e9galement de la participation des investisseurs particuliers \u00e0 travers la plateforme PrimaryBid. Gr\u00e2ce \u00e0 la validation du design de la phase 3, aux r\u00e9sultats pr\u00e9liminaires de Phase I\/ II encourageants et au succ\u00e8s de cette op\u00e9ration, nous lancerons la Phase 3 pivot de Batten-1 d\u00e8s la fin de l\u2019ann\u00e9e 2023. Nous visons ainsi son approbation et sa commercialisation d\u00e8s 2027, ce qui ferait de Batten-1 le premier produit enregistr\u00e9 dans la maladie de Batten dans le monde. \u00bb, conclut Mathieu Charv\u00e9riat, directeur g\u00e9n\u00e9ral de Theranexus. Pour en savoir plus sur Theranexus&nbsp;:&nbsp;https:\/\/www.theranexus.com\/fr\/\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.incuballiance.fr\/en\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros\/\" \/>\n<meta property=\"og:site_name\" content=\"IncubAlliance\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-18T14:41:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-07T14:55:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.incuballiance.fr\/wp-content\/uploads\/2023\/06\/Actu-IncubAlliance-Visuels-site-1-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Alexis Arnou\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alexis Arnou\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.incuballiance.fr\\\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.incuballiance.fr\\\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros\"},\"author\":{\"name\":\"Alexis Arnou\",\"@id\":\"https:\\\/\\\/www.incuballiance.fr\\\/#\\\/schema\\\/person\\\/3c8c243fb0e07f9a44a59e30d8a4cb0c\"},\"headline\":\"\u00a0Theranexus annonce une lev\u00e9e de fonds de 3,1 millions d\u2019euros\",\"datePublished\":\"2023-07-18T14:41:00+00:00\",\"dateModified\":\"2025-10-07T14:55:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.incuballiance.fr\\\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros\"},\"wordCount\":484,\"publisher\":{\"@id\":\"https:\\\/\\\/www.incuballiance.fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.incuballiance.fr\\\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.incuballiance.fr\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Actu-IncubAlliance-Visuels-site-1-scaled.jpg\",\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.incuballiance.fr\\\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros\",\"url\":\"https:\\\/\\\/www.incuballiance.fr\\\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros\",\"name\":\"\u00a0Theranexus annonce une lev\u00e9e de fonds de 3,1 millions d\u2019euros - IncubAlliance\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.incuballiance.fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.incuballiance.fr\\\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.incuballiance.fr\\\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.incuballiance.fr\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Actu-IncubAlliance-Visuels-site-1-scaled.jpg\",\"datePublished\":\"2023-07-18T14:41:00+00:00\",\"dateModified\":\"2025-10-07T14:55:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.incuballiance.fr\\\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.incuballiance.fr\\\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.incuballiance.fr\\\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros#primaryimage\",\"url\":\"https:\\\/\\\/www.incuballiance.fr\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Actu-IncubAlliance-Visuels-site-1-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/www.incuballiance.fr\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Actu-IncubAlliance-Visuels-site-1-scaled.jpg\",\"width\":2560,\"height\":1440},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.incuballiance.fr\\\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.incuballiance.fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u00a0Theranexus annonce une lev\u00e9e de fonds de 3,1 millions d\u2019euros\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.incuballiance.fr\\\/#website\",\"url\":\"https:\\\/\\\/www.incuballiance.fr\\\/\",\"name\":\"IncubAlliance\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.incuballiance.fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.incuballiance.fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.incuballiance.fr\\\/#organization\",\"name\":\"IncubAlliance\",\"url\":\"https:\\\/\\\/www.incuballiance.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.incuballiance.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.incuballiance.fr\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/logo-incuballiance.svg\",\"contentUrl\":\"https:\\\/\\\/www.incuballiance.fr\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/logo-incuballiance.svg\",\"caption\":\"IncubAlliance\"},\"image\":{\"@id\":\"https:\\\/\\\/www.incuballiance.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.incuballiance.fr\\\/#\\\/schema\\\/person\\\/3c8c243fb0e07f9a44a59e30d8a4cb0c\",\"name\":\"Alexis Arnou\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c97adc1161b42b51ddf6cd499fd7740c4b8925d6bcd6cc96f7294637183f746e?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c97adc1161b42b51ddf6cd499fd7740c4b8925d6bcd6cc96f7294637183f746e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c97adc1161b42b51ddf6cd499fd7740c4b8925d6bcd6cc96f7294637183f746e?s=96&d=mm&r=g\",\"caption\":\"Alexis Arnou\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u00a0Theranexus announces a \u20ac3.1 million fundraising round - IncubAlliance","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.incuballiance.fr\/en\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros\/","og_locale":"en_US","og_type":"article","og_title":"\u00a0Theranexus annonce une lev\u00e9e de fonds de 3,1 millions d\u2019euros - IncubAlliance","og_description":"Soci\u00e9t\u00e9 biopharmaceutique innovante dans le traitement des maladies neurologiques rares, pass\u00e9e par les rangs d\u2019IncubAlliance, Theranexus annonce une lev\u00e9e de fonds de 3,1 millions d\u2019euros. Issue du CEA, sp\u00e9cialis\u00e9e dans le traitement des maladies neurologiques rares et pionni\u00e8re dans le d\u00e9veloppement de candidats m\u00e9dicaments ciblant \u00e0 la fois les neurones et les cellules gliales, Theranexus en a fait du chemin depuis sa sortie d\u2019IncubAlliance. Cot\u00e9e sur le march\u00e9 Euronext Growth \u00e0 Paris, la soci\u00e9t\u00e9 annonce aujourd\u2019hui la r\u00e9alisation d\u2019une lev\u00e9e de fonds de 3,1 millions d\u2019euros,\u00a0dont environ 2,5 millions d\u2019euros ont \u00e9t\u00e9 souscrits par des investisseurs sp\u00e9cialis\u00e9s et strat\u00e9giques, via la construction acc\u00e9l\u00e9r\u00e9e d\u2019un livre d\u2019ordres, et 0,6 million d\u2019euros souscrits par des investisseurs particuliers via la plateforme PrimaryBid. Disposant actuellement d\u2019une plateforme unique d\u2019identification de caract\u00e9risation de candidats m\u00e9dicaments de th\u00e9rapie innovante dans le domaine des troubles neurologiques rares et d\u2019un premier candidat m\u00e9dicament en d\u00e9veloppement clinique dans la maladie de Batten, Theranexus entend donc passer \u00e0 la vitesse sup\u00e9rieure gr\u00e2ce \u00e0 cette lev\u00e9e de fonds. Combin\u00e9 aux fonds existant de la soci\u00e9t\u00e9, le produit de cette lev\u00e9e contribuera en effet au financement de la phase 3 pivot du candidat m\u00e9dicament Batten-1, visant \u00e0 soigner les patients p\u00e9diatriques atteints d\u2019une maladie neurologique rare, la maladie de Batten. Une phase 3 qui devrait d\u00e9buter d\u00e8s la fin du second semestre 2023 et s\u2019achever fin 2026, avec des co\u00fbts estim\u00e9s \u00e0 5 millions d\u2019euros par an pendant 3 ans. Les fonds de cette lev\u00e9e seront \u00e9galement destin\u00e9s \u00e0 financer les autres activit\u00e9s de recherche et d\u00e9veloppement de la soci\u00e9t\u00e9\u0301, ainsi que ses besoins g\u00e9n\u00e9raux. \u00ab Nous remercions tous nos investisseurs et nouveaux actionnaires pour leur confiance et leur engagement \u00e0 nos c\u00f4t\u00e9s dans cette op\u00e9ration. Nous tenons \u00e9galement \u00e0 saluer la participation de la Fondation BBDF qui a renouvel\u00e9\u0301 sa confiance dans notre capacit\u00e9\u0301 \u00e0 mener \u00e0 bien le d\u00e9veloppement de Batten-1 afin d\u2019apporter une solution th\u00e9rapeutique aux patients atteints par la maladie de Batten. Nous nous r\u00e9jouissons \u00e9galement de la participation des investisseurs particuliers \u00e0 travers la plateforme PrimaryBid. Gr\u00e2ce \u00e0 la validation du design de la phase 3, aux r\u00e9sultats pr\u00e9liminaires de Phase I\/ II encourageants et au succ\u00e8s de cette op\u00e9ration, nous lancerons la Phase 3 pivot de Batten-1 d\u00e8s la fin de l\u2019ann\u00e9e 2023. Nous visons ainsi son approbation et sa commercialisation d\u00e8s 2027, ce qui ferait de Batten-1 le premier produit enregistr\u00e9 dans la maladie de Batten dans le monde. \u00bb, conclut Mathieu Charv\u00e9riat, directeur g\u00e9n\u00e9ral de Theranexus. Pour en savoir plus sur Theranexus&nbsp;:&nbsp;https:\/\/www.theranexus.com\/fr\/","og_url":"https:\/\/www.incuballiance.fr\/en\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros\/","og_site_name":"IncubAlliance","article_published_time":"2023-07-18T14:41:00+00:00","article_modified_time":"2025-10-07T14:55:27+00:00","og_image":[{"width":2560,"height":1440,"url":"https:\/\/www.incuballiance.fr\/wp-content\/uploads\/2023\/06\/Actu-IncubAlliance-Visuels-site-1-scaled.jpg","type":"image\/jpeg"}],"author":"Alexis Arnou","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Alexis Arnou","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.incuballiance.fr\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros#article","isPartOf":{"@id":"https:\/\/www.incuballiance.fr\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros"},"author":{"name":"Alexis Arnou","@id":"https:\/\/www.incuballiance.fr\/#\/schema\/person\/3c8c243fb0e07f9a44a59e30d8a4cb0c"},"headline":"\u00a0Theranexus annonce une lev\u00e9e de fonds de 3,1 millions d\u2019euros","datePublished":"2023-07-18T14:41:00+00:00","dateModified":"2025-10-07T14:55:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.incuballiance.fr\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros"},"wordCount":484,"publisher":{"@id":"https:\/\/www.incuballiance.fr\/#organization"},"image":{"@id":"https:\/\/www.incuballiance.fr\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros#primaryimage"},"thumbnailUrl":"https:\/\/www.incuballiance.fr\/wp-content\/uploads\/2023\/06\/Actu-IncubAlliance-Visuels-site-1-scaled.jpg","articleSection":["Actualit\u00e9s"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.incuballiance.fr\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros","url":"https:\/\/www.incuballiance.fr\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros","name":"\u00a0Theranexus announces a \u20ac3.1 million fundraising round - IncubAlliance","isPartOf":{"@id":"https:\/\/www.incuballiance.fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.incuballiance.fr\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros#primaryimage"},"image":{"@id":"https:\/\/www.incuballiance.fr\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros#primaryimage"},"thumbnailUrl":"https:\/\/www.incuballiance.fr\/wp-content\/uploads\/2023\/06\/Actu-IncubAlliance-Visuels-site-1-scaled.jpg","datePublished":"2023-07-18T14:41:00+00:00","dateModified":"2025-10-07T14:55:27+00:00","breadcrumb":{"@id":"https:\/\/www.incuballiance.fr\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.incuballiance.fr\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.incuballiance.fr\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros#primaryimage","url":"https:\/\/www.incuballiance.fr\/wp-content\/uploads\/2023\/06\/Actu-IncubAlliance-Visuels-site-1-scaled.jpg","contentUrl":"https:\/\/www.incuballiance.fr\/wp-content\/uploads\/2023\/06\/Actu-IncubAlliance-Visuels-site-1-scaled.jpg","width":2560,"height":1440},{"@type":"BreadcrumbList","@id":"https:\/\/www.incuballiance.fr\/theranexus-annonce-une-levee-de-fonds-de-31-millions-deuros#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.incuballiance.fr\/"},{"@type":"ListItem","position":2,"name":"\u00a0Theranexus annonce une lev\u00e9e de fonds de 3,1 millions d\u2019euros"}]},{"@type":"WebSite","@id":"https:\/\/www.incuballiance.fr\/#website","url":"https:\/\/www.incuballiance.fr\/","name":"IncubAlliance","description":"","publisher":{"@id":"https:\/\/www.incuballiance.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.incuballiance.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.incuballiance.fr\/#organization","name":"IncubAlliance","url":"https:\/\/www.incuballiance.fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.incuballiance.fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.incuballiance.fr\/wp-content\/uploads\/2025\/04\/logo-incuballiance.svg","contentUrl":"https:\/\/www.incuballiance.fr\/wp-content\/uploads\/2025\/04\/logo-incuballiance.svg","caption":"IncubAlliance"},"image":{"@id":"https:\/\/www.incuballiance.fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.incuballiance.fr\/#\/schema\/person\/3c8c243fb0e07f9a44a59e30d8a4cb0c","name":"Alexis Arnou","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/c97adc1161b42b51ddf6cd499fd7740c4b8925d6bcd6cc96f7294637183f746e?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/c97adc1161b42b51ddf6cd499fd7740c4b8925d6bcd6cc96f7294637183f746e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c97adc1161b42b51ddf6cd499fd7740c4b8925d6bcd6cc96f7294637183f746e?s=96&d=mm&r=g","caption":"Alexis Arnou"}}]}},"_links":{"self":[{"href":"https:\/\/www.incuballiance.fr\/en\/wp-json\/wp\/v2\/posts\/7081","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.incuballiance.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.incuballiance.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.incuballiance.fr\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.incuballiance.fr\/en\/wp-json\/wp\/v2\/comments?post=7081"}],"version-history":[{"count":1,"href":"https:\/\/www.incuballiance.fr\/en\/wp-json\/wp\/v2\/posts\/7081\/revisions"}],"predecessor-version":[{"id":8455,"href":"https:\/\/www.incuballiance.fr\/en\/wp-json\/wp\/v2\/posts\/7081\/revisions\/8455"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.incuballiance.fr\/en\/wp-json\/wp\/v2\/media\/8453"}],"wp:attachment":[{"href":"https:\/\/www.incuballiance.fr\/en\/wp-json\/wp\/v2\/media?parent=7081"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.incuballiance.fr\/en\/wp-json\/wp\/v2\/categories?post=7081"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.incuballiance.fr\/en\/wp-json\/wp\/v2\/tags?post=7081"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}